Mymetics

Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company focused on
developing vaccines with a Research Lab in the Netherlands. The company is registered in the US and
trades on the OTCQB, a venture stage market place for companies that are current in their reporting.

With only 27 diseases are being addressed by vaccines today, it is clear the world needs many more
preventative vaccines.

Global Leader in virosome and membrane protein expertise

With more than 30 years of experience in the field of virosome vaccines, Mymetics has gained a unique
R&D expertise, specialist know-how and intellectual property rights directly related to virosome
based vaccines, making it the global leader in this field. Our team consist of the original inventors of
the virosome technology, a platform that can be adapted to many vaccines.

Unique approach

Virosomes are lipid-based carriers (envelopes) containing the functional fusion viral proteins and
natural membrane proteins of the natural virus. These lipid-based viral envelopes can be combined
with additional rationally designed antigens or adjuvants if needed.

Virosomes can be made of any enveloped virus and are mainly used for two applications. The first vaccine
application is against the original enveloped virus from which the virosome is made, i.e. the Influenza
virus, Respiratory Syncytial virus, Chikungunya, Herpes Simplex virus, etc. The second application is
using the influenza virus virosome as a carrier for specific vaccinal antigens that can be derived from
non-enveloped or enveloped viruses like HIV, as well as from more complex pathogens such as the
Plasmodium falciparum causing malaria. Influenza virosome can also be used for immunotherapy
against cancer and could be extended to other fields like allergies and autoimmune diseases.

Our vaccines are designed to induce protection against early transmission and infection, focusing
both on the mucosal immune response as a first-line defense and the systemic humoral (blood)
immune response, which, for some pathogens, may be essential for the development of an effective
prophylactic vaccine.

Virosomes based vaccines are designed to maintain the immunogenicity of a live-attenuated virus but
with the safety of a killed virus.

MyMetics3
Rich Pipeline
Our unique approach has resulted in the development a rich pipeline of 5 vaccine candidates for HIV-
1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncytial
Virus (RSV) vaccine. In January 2016, Mymetics started a discovery program to develop Chikungunya
and ZIKA vaccine candidates.

Validation and Partnerships

Our delivery platform is being validated through partnership with leading pharmaceutical or research
organisations, including PATH-MVI and the Bill and Melinda Gates Foundation. Since April 2015,
Mymetics is leading a project with a consortium of companies which have been awarded a total of €8.4
million in grant financing. This innovation project has as objective to develop cold-chain independent
and thermostable virosome vaccines. The project will receive €5.3 million funding from the European
Union’s Horizon 2020 research and innovation programme under Grant Agreement No 646122. and
€3.1 million from the Swiss Secretariat for Education, Research and Innovation.

Mymetics’ objective is to build a specialized and strong virosome vaccine research and development
company, with industry leading partnerships and to advance our vaccine candidates for infectious
diseases through clinical trials and bring them to the market.

 

 

Route de la Corniche 4, 1066 Epalinges, Switzerland
+41 21 653 4535
http://www.mymetics.com